NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Forecast & News

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Merrimack Pharmaceuticals declared a -- dividend on Wednesday, December 4th. Investors of record on Monday, December 16th will be paid a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date is Friday, December 13th. View Merrimack Pharmaceuticals' Dividend History.

Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its quarterly earnings data on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14. View Merrimack Pharmaceuticals' Earnings History.

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Merrimack Pharmaceuticals.

Media stories about MACK stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 501,100 shares, a decrease of 6.1% from the January 15th total of 533,500 shares. Based on an average daily trading volume, of 41,700 shares, the days-to-cover ratio is currently 12.0 days. Currently, 4.0% of the company's stock are short sold. View Merrimack Pharmaceuticals' Current Options Chain.

Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Rite Aid (RAD), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Novavax (NVAX), Amicus Therapeutics (FOLD), Exelixis (EXEL), Gilead Sciences (GILD), Bausch Health Companies (BHC) and Verastem (VSTM).

Merrimack Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sepio Capital LLC (2.96%) and Renaissance Technologies LLC (0.25%). Company insiders that own Merrimack Pharmaceuticals stock include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc and Lp 22Nw. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

MACK stock was acquired by a variety of institutional investors in the last quarter, including Sepio Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc and Lp 22Nw. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MACK stock can currently be purchased for approximately $3.22.

Merrimack Pharmaceuticals has a market capitalization of $43.03 million. Merrimack Pharmaceuticals employs 27 workers across the globe.View Additional Information About Merrimack Pharmaceuticals.

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com/.

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]